Not medical care
Information is educational and general. It is not a diagnosis, individual prediction, testing or treatment recommendation, or a substitute for professional care.
DOCUMENTS · 30 AUG 2026
Medical and genetic information
A genetic result has meaning only with the exact variant, method, specimen, symptoms, family and clinical question.
Medicines
Do not start, stop or change a medicine or dose because of this website. Pharmacogenetic results apply only to a specific medicine, indication and patient after clinical review.
Confirmation
Any potentially significant result requires appropriate confirmation and qualified professional assessment. A VUS is not a positive diagnostic or predictive result.
Variant reference
A match to a ClinVar designation does not confirm that the variant was actually detected in the user. No match does not mean that a variant is benign, that a test is negative, or that genetic risk is absent.
Evidence navigator
The evidence navigator is not a prescribing system. It displays an exact limited regulatory relationship, incomplete context or a blocked output. A medicine name is shown only as content of the primary source; the algorithm does not assess contraindications, the complete diagnosis, alternatives, interactions, access or patient goals, rank regimens, or calculate dose.
Medication pharmacogenetics
The navigator confirms only the scope of a specific professional guideline and provides questions for a clinician. It does not translate a raw variant or star allele into phenotype, assess the complete medicine list, contraindications, interactions, liver and kidney function, current toxicity, effectiveness or treatment goals. A ‘normal’ phenotype or negative HLA result is not a safety guarantee.
Inherited cardiometabolic conditions
A gene name or pathogenic/likely pathogenic variant is not a clinical diagnosis. The exact gene–condition relationship, mechanism, technical coverage, phenotype and family context are required. A VUS does not establish the condition and is not a basis for treatment or targeted testing of unaffected relatives; a negative result depends on the assay and any known familial variant.
Rare disease
Panels, CMA, exome and genome answer different technical questions. Method selection requires a structured phenotype, assessment of the likely inheritance pattern and variant class, prior assays and the clinical laboratory’s capabilities. A VUS does not confirm diagnosis, while a negative result may reflect coverage or analysis limits.
Reproductive genetics and newborn screening
Carrier screening, NIPT/cfDNA, CVS or amniocentesis with a laboratory assay, PGT and newborn screening have different purposes, specimens and result types. A positive screen or no-call requires timely professional assessment and, where relevant, diagnostic confirmation; a negative screen does not exclude all genetic or congenital conditions. If a newborn appears unwell, care must not be delayed for repeat screening.
Research oncology cohorts
Aggregate SSM frequency in NCI GDC describes only the selected research cohort, available data type and stated denominator. It does not confirm a patient variant, account for morphology, stage, individual assay quality or a drug indication, evaluate treatment effectiveness, or provide an individual prognosis.
Oncology
A tumour finding is not automatically inherited and does not prescribe a medicine. Decisions include morphology, stage, line, prior treatment, patient status, current labels and tumour-board review.
Children
Testing a child can be justified by symptoms, a specific family risk or expected medical benefit in childhood. It is not a required tool for choosing sport, school, diet, career or developmental potential.
Urgent care
This website is not an emergency service. Contact your local emergency service for acute deterioration.
The website controller is ООО «НПО НТ». This page forms part of GENES ≠ FATE’s own document set and reflects the site’s current functions.
Ethical principles →Found an error? →